Literature DB >> 24106726

Subsequent entry biologics - opportunities and challenges.

Subrata Ghosh.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24106726      PMCID： PMC3805335          DOI： 10.1155/2013/634176

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN： 0835-7900            Impact factor:   3.522


× No keyword cloud information.
  3 in total

Review 1.  Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics.

Authors:  Shane M Devlin; Brian Bressler; Charles N Bernstein; Richard N Fedorak; Alain Bitton; Harminder Singh; Brian G Feagan
Journal:  Can J Gastroenterol       Date:  2013-10       Impact factor: 3.522

2.  Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.

Authors:  Gert Van Assche; Séverine Vermeire; Vera Ballet; Frederik Gabriels; Maja Noman; Geert D'Haens; Christophe Claessens; Evelien Humblet; Niels Vande Casteele; Ann Gils; Paul Rutgeerts
Journal:  Gut       Date:  2011-09-23       Impact factor: 23.059

Review 3.  Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.

Authors:  R Khanna; B D Sattin; W Afif; E I Benchimol; E-J Bernard; A Bitton; B Bressler; R N Fedorak; S Ghosh; G R Greenberg; J K Marshall; R Panaccione; E G Seidman; M S Silverberg; A H Steinhart; R Sy; G Van Assche; T D Walters; W J Sandborn; B G Feagan
Journal:  Aliment Pharmacol Ther       Date:  2013-07-14       Impact factor: 8.171
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.